Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Inclusion Criteria: All subjects * Age 18-40. * Read, signed and dated informed consent. * Women of childbearing potential must use an acceptable method of contraception Group 1: Healthy subjects * No history of atopic dermatitis as documented in the patient file * No active atopic dermatitis * No other atopic disorders such as asthma or allergic rhinitis. * Prick test without clinical significance * IgE within normal range Group 2: Subjects with history of atopic dermatitis Group 3: Subjects with mild active atopic dermatitis \- SCORAD 1 - 15. Group 4: Subjects with mild allergic rhinitis * At least one active allergic rhinitis phase during last year. Exclusion Criteria: * Known or suspected history of smallpox vaccination or typical vaccinia scar. * Positive test result in MVA specific ELISA at screening. * Positive result in HIV or HCV antibody test at screening. * Surface antigen of Hepatitis B Virus (HBsAg) positive at screening. * Pregnant or breast-feeding women. * Positive pregnancy test at screening and/or within 24 hours prior to vaccination. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the institutional upper limit of normal. * Positive urine glucose by dipstick or urine analysis. * Inadequate renal function defined as a serum creatinine above the institutional upper limit of normal; urine protein \>30 mg/dl or trace proteinuria (by urine analysis or dipstick); and a calculated creatinine clearance \<80 ml/min. * Electrocardiogram (ECG) with clinical significance. * Hemoglobin \<11 g/dl; White blood cells less than 2,500 and more than 11,000/mm3; Platelets less than 140,000/mm3. * Uncontrolled serious infection i.e. not responding to antimicrobial therapy. * History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject. * History of or active autoimmune disease. * Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment. * History of malignancy. * History or clinical manifestation of clinically significant mental illness or haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders. * Any condition which might interfere with study objectives. * History of immunodeficiency. * History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or other heart condition under the care of a doctor. * Three or more of the following risk factors: High blood pressure, high blood cholesterol, diabetes mellitus or high blood sugar, a first degree relative who had a heart condition before the age of 50, smoking cigarettes. * History of chronic alcohol abuse and/or intravenous drug abuse. * History of allergic reactions likely to be exacerbated by any component of the vaccine. * History of anaphylaxis or severe allergic reaction. * Acute disease (illness with or without a fever) at the time of enrollment. * Any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion. * Chronic administration of immuno-suppressant or immune-modifying drugs. * Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy. * Administration or planned administration of immunoglobulins and/or any blood -- Use of any investigational or non-registered drug. * Blood donation 8 weeks in advance or during study participation.